博創科技(300548.SZ):4月6日繼續停牌、預計停牌不超2個交易日
格隆匯4月1日丨博創科技(300548.SZ)公佈,公司於2022年4月1日收到公司控股股東、實際控制人ZHU WEI及其配偶WANGXIAOHONG的通知,其向特定對象轉讓所持部分公司股份及委託表決權的事項仍在與交易對方進一步磋商中,尚未簽署正式交易協議。為保證信息披露的公平與公正,維護廣大投資者利益,避免造成公司股價異常波動,根據有關規定,經公司向深圳證券交易所申請,公司股票自2022年4月6日上午開市起繼續停牌,預計停牌時間不超過2個交易日,累計停牌時間不超過4個交易日。待有關事項確定後,公司將及時發佈公吿並申請股票復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.